Developer docs
API playgroundTry for free, no card

Search company profiles

Acetylon Pharmaceuticals

Full company profile

uuid0008ygu

Namestring
Acetylon Pharmaceuticals
Websiteurl
acetylon.com
Company typeenum
Private
Founded yearint
2008
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
epigenetic drug development, histone deacetylase inhibitors, small molecule therapeutics, oncology drug discovery, precision medicine drugs
Industry1 code
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Epigenetic Oncology Therapeutics
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Acetylon Pharmaceuticals develops and manufactures small molecule drugs that target histone deacetylase (HDAC) enzymes to realize the therapeutic potential of epigenetic modulation. The company's offerings are primarily directed at oncology applications, particularly solid tumors, leveraging precision medicine approaches to gene expression regulation.

Differentiator
Functional benefit
Problem solved
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Focused on chromatin biology and dysregulated gene expression in cancer and other diseases. Directly comparable gene-expression-modulation approach via chromatin regulators, in oncology.

TypeEmerging player
Description

Precision oncology company developing targeted therapies against genetically defined cancers. Comparable in oncology focus and small-molecule targeted approach, though mechanism differs (kinase/epigenetic-adjacent targets).

TypeDirect peer
Description

Epigenetics-focused oncology company developing small-molecule inhibitors of chromatin-modifying enzymes (EZH2, EZH1, BET). Highly comparable as a small-molecule epigenetics platform targeting gene expression regulation in cancer.

TypeEmerging player
Description

Develops targeted protein degraders (dacians) with epigenetic targets in oncology. Comparable as a small-molecule platform company exploiting chromatin/epigenetic biology in cancer, with a more differentiated degrader modality.

TypeDirect peer
Description

Develops HDAC inhibitors and PI3K inhibitors for cancer and inflammation. Directly comparable HDAC mechanism focus, similar early-stage development profile.

6NewLink Genetics
TypeEmerging player
Description

Immuno-oncology company whose pipeline has included HDAC-related combinations and IDO pathway inhibitors. Comparable as a small-cap oncology company exploring epigenetic/immune-modulatory combinations.

TypeDirect peer
Description

Epigenetics drug developer (now part of Ipsen) focused on EZH2 inhibition for cancer. Same broad category — small-molecule drugs targeting chromatin/epigenetic mechanisms in oncology — and similar scale and stage profile.

TypeDirect peer
Description

Clinical-stage oncology company developing entinostat, an HDAC inhibitor, in combination with immuno-oncology agents. Directly comparable mechanism (HDAC inhibition) and oncology focus, making it the closest therapeutic-area peer to Acetylon.

9Bristol Myers Squibb
TypeBroad incumbent
Description

Global biopharmaceutical company with deep oncology and hematology franchises. Comparable as a broad incumbent acquirer of epigenetics/HDAC assets (Celgene, Acetylon's prior lead investor, was acquired by BMS) and as a competitive large-pharma presence in HDAC-adjacent oncology.

TypeDirect peer
Description

Developed small-molecule HDAC inhibitors for oncology (birinapant and related SMAC mimetic/HDAC programs). Direct HDAC mechanism peer in oncology with comparable size and stage profile.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Acetylon Pharmaceuticals

Epigenetic Oncology Therapeuticsacetylon.com

Acetylon Pharmaceuticals firmographics

Firmographics
Name
Acetylon Pharmaceuticals
Website
https://acetylon.com
Company type
Private
Founded year
2008
Headcount range
1–10 employees
Ownership category
akta.pro rank

Acetylon Pharmaceuticals industry classification

Industry
Product category
Epigenetic Oncology Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals

Keywords

  • Epigenetic drug development
  • Histone deacetylase inhibitors
  • Small molecule therapeutics
  • Oncology drug discovery
  • Precision medicine drugs

Where Acetylon Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

Acetylon Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Acetylon Pharmaceuticals product offering

Product offering

Core offering

Acetylon Pharmaceuticals develops and manufactures small molecule drugs that target histone deacetylase (HDAC) enzymes to realize the therapeutic potential of epigenetic modulation. The company's offerings are primarily directed at oncology applications, particularly solid tumors, leveraging precision medicine approaches to gene expression regulation.

Differentiator

Problem solved

Functional benefit

Companies that use Acetylon Pharmaceuticals

Customer profile

Segments2 records

Ideal customer profiles2 records

Acetylon Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Acetylon Pharmaceuticals partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights3 records

Acetylon Pharmaceuticals competitors and assessment

Company assessment

Emerging players

  • Foghorn Therapeutics: Focused on chromatin biology and dysregulated gene expression in cancer and other diseases. Directly comparable gene-expression-modulation approach via chromatin regulators, in oncology.
  • Mirati Therapeutics: Precision oncology company developing targeted therapies against genetically defined cancers. Comparable in oncology focus and small-molecule targeted approach, though mechanism differs (kinase/epigenetic-adjacent targets).
  • C4 Therapeutics: Develops targeted protein degraders (dacians) with epigenetic targets in oncology. Comparable as a small-molecule platform company exploiting chromatin/epigenetic biology in cancer, with a more differentiated degrader modality.
  • NewLink Genetics: Immuno-oncology company whose pipeline has included HDAC-related combinations and IDO pathway inhibitors. Comparable as a small-cap oncology company exploring epigenetic/immune-modulatory combinations.

Direct peers

  • Constellation Pharmaceuticals: Epigenetics-focused oncology company developing small-molecule inhibitors of chromatin-modifying enzymes (EZH2, EZH1, BET). Highly comparable as a small-molecule epigenetics platform targeting gene expression regulation in cancer.
  • Karus Therapeutics: Develops HDAC inhibitors and PI3K inhibitors for cancer and inflammation. Directly comparable HDAC mechanism focus, similar early-stage development profile.
  • Epizyme: Epigenetics drug developer (now part of Ipsen) focused on EZH2 inhibition for cancer. Same broad category — small-molecule drugs targeting chromatin/epigenetic mechanisms in oncology — and similar scale and stage profile.
  • Syndax Pharmaceuticals: Clinical-stage oncology company developing entinostat, an HDAC inhibitor, in combination with immuno-oncology agents. Directly comparable mechanism (HDAC inhibition) and oncology focus, making it the closest therapeutic-area peer to Acetylon.
  • TetraLogic Pharmaceuticals: Developed small-molecule HDAC inhibitors for oncology (birinapant and related SMAC mimetic/HDAC programs). Direct HDAC mechanism peer in oncology with comparable size and stage profile.

Broad incumbents

  • Bristol Myers Squibb: Global biopharmaceutical company with deep oncology and hematology franchises. Comparable as a broad incumbent acquirer of epigenetics/HDAC assets (Celgene, Acetylon's prior lead investor, was acquired by BMS) and as a competitive large-pharma presence in HDAC-adjacent oncology.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Acetylon Pharmaceuticals social profiles

Digital presence

Acetylon Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Acetylon Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles3 records

Acetylon Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Acetylon Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acetylon Pharmaceuticals

What does Acetylon Pharmaceuticals do?

Acetylon Pharmaceuticals develops and manufactures small molecule drugs that target histone deacetylase (HDAC) enzymes to realize the therapeutic potential of epigenetic modulation. The company's offerings are primarily directed at oncology applications, particularly solid tumors, leveraging precision medicine approaches to gene expression regulation.

When was Acetylon Pharmaceuticals founded?

Acetylon Pharmaceuticals was founded in 2008. It employs 1 to 10 people.

Where is Acetylon Pharmaceuticals based?

Acetylon Pharmaceuticals is headquartered in Boston, United States, in the North America region.

Who are Acetylon Pharmaceuticals's main competitors?

Emerging players on record are Foghorn Therapeutics, Mirati Therapeutics, C4 Therapeutics and NewLink Genetics. Direct peers are Constellation Pharmaceuticals, Karus Therapeutics, Epizyme, Syndax Pharmaceuticals and TetraLogic Pharmaceuticals. Bristol Myers Squibb is listed as a broad incumbent.

Does Acetylon Pharmaceuticals have an API?

No public API is recorded for Acetylon Pharmaceuticals.

What industry is Acetylon Pharmaceuticals in?

Acetylon Pharmaceuticals's product category is Epigenetic Oncology Therapeutics. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals